What is risperidone?

What is Risperidone

Risperidone is an atypical (second-generation) antipsychotic medication that works primarily through combined antagonism of serotonin 5-HT2 and dopamine D2 receptors. 1

Drug Classification and Mechanism

• Risperidone is a benzisoxazole derivative that is chemically distinct from other antipsychotic agents 1, 2
• The mechanism combines potent dopamine D2 receptor blockade with serotonin 5-HT2 receptor antagonism, which is proposed to mediate its therapeutic effects 1
• The drug also has high affinity for α1 and α2 adrenergic receptors and H1 histaminergic receptors, with lower affinity for other serotonin receptor subtypes 1
• Risperidone has no anticholinergic activity, distinguishing it from many traditional antipsychotics 3

Pharmacokinetics

• Oral bioavailability is approximately 70%, with peak plasma concentrations occurring at about 1 hour after administration 1, 2
• The drug is extensively metabolized by CYP 2D6 to 9-hydroxyrisperidone, an active metabolite with similar pharmacological activity to the parent compound 1
• Clinical effects result from combined concentrations of risperidone plus 9-hydroxyrisperidone 1, 2
• Steady-state concentrations are reached in 1 day for extensive metabolizers and approximately 5 days for poor metabolizers 1
• Food does not affect absorption, allowing administration with or without meals 1

FDA-Approved Indications

• Schizophrenia in adults and adolescents aged 13-17 years 1
• Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy or in combination with lithium or valproate 4, 5
• Irritability associated with autistic disorder in children and adolescents aged 5-16 years 4
• Lithium is the only agent FDA-approved for bipolar disorder in youth aged 12 years and older, though risperidone is approved for acute mania in adults 4

Clinical Efficacy Profile

• Risperidone demonstrates comparable overall efficacy to haloperidol for positive symptoms of schizophrenia, but with potentially greater effects on negative symptoms 2, 6
• The drug shows faster onset of antipsychotic action compared to traditional neuroleptics 6
• At clinically effective doses, risperidone causes no more extrapyramidal side effects than placebo, though EPS frequency increases in a dose-dependent manner at higher doses 3
• Among atypical antipsychotics, risperidone appears most likely to produce extrapyramidal side effects 4

Common Side Effects and Safety Concerns

Neurological Effects

• Extrapyramidal symptoms (EPS), including acute dystonia, akathisia, and Parkinsonian syndrome, can occur, particularly at higher doses 4
• Cases of neuroleptic malignant syndrome and tardive dyskinesia have been reported in adults and adolescents 4
• The risk of EPS is lower than with traditional neuroleptics but higher than other atypical agents 4

Metabolic and Endocrine Effects

• Weight gain can be extreme and represents the most common significant problem with atypical antipsychotics 4
• Hyperprolactinemia is common, which can result in amenorrhea and sexual dysfunction 3

Cardiovascular Effects

• Orthostatic hypotension can occur 4
• QT interval prolongation of 0-5 milliseconds is minimal compared to other antipsychotics 4
• Risperidone is associated with increased risk of ventricular arrhythmia and sudden cardiac death (adjusted OR 1.39,95% CI 1.13-1.72) in vulnerable populations 4

Hematological Effects

• Rare cases of leukocytopenia have been reported in adolescents 4

Hepatic Effects

• Transient elevations in hepatic transaminase levels may occur 4
• Two cases of liver enzyme abnormalities with fatty infiltrates have been reported in adolescent males, suggesting baseline and periodic liver function monitoring may be prudent 4

Dosing Considerations

• Typical starting doses for adults range from 2 mg/day, with dose adjustments based on response and tolerability 4
• For acute agitation in adolescents, doses of 0.5-1 mg orally or intramuscularly may be used, with repeat dosing every 30-60 minutes as needed 4
• Optimal dosing for relapse prevention appears to be 0.6-<1.4 defined daily doses (DDDs) per day based on real-world effectiveness data 7
• Lower doses should be used in elderly or frail patients, with gradual titration 4

Special Clinical Applications

• Risperidone may be useful for treatment-resistant obsessive-compulsive disorder when added to serotonin reuptake inhibitors 8, 9, 10
• The drug has shown benefit for psychosis, agitation, and rapid cycling in bipolar disorder 8
• For bipolar maintenance after manic episode remission, continuation for 24 weeks appears beneficial, though continuation of risperidone beyond this period does not further reduce relapse risk 11
• Long-acting injectable formulations are available for patients with adherence difficulties 4